Depletion of the histone chaperone tNASP inhibits proliferation and induces apoptosis in prostate cancer PC-3 cells by Alekseev, Oleg M et al.
RESEARCH Open Access
Depletion of the histone chaperone tNASP
inhibits proliferation and induces apoptosis in
prostate cancer PC-3 cells
Oleg M Alekseev
1,2*, Richard T Richardson
1, James K Tsuruta
3 and Michael G O’Rand
1
Abstract
Background: NASP (Nuclear Autoantigenic Sperm Protein) is a histone chaperone that is present in all dividing
cells. NASP has two splice variants: tNASP and sNASP. Only cancer, germ, transformed, and embryonic cells have a
high level of expression of the tNASP splice variant. We examined the consequences of tNASP depletion for
prostate cancer PC-3 cells.
Methods: tNASP was depleted from prostate cancer PC-3 cells, cervical cancer HeLa cells, and prostate epithelial
PWR-1E cells using lentivirus expression of tNASP shRNA. Cell cycle changes were studied by proliferation assay
with CFSE labeling and double thymidine synchronization. Gene expression profiles were detected using RT
2Profiler
PCR Array, Western and Northern blotting.
Results: PC-3 and HeLa cells showed inhibited proliferation, increased levels of cyclin-dependant kinase inhibitor
p21 protein and apoptosis, whereas non-tumorigenic PWR-1E cells did not. All three cell types showed decreased
levels of HSPA2. Supporting in vitro experiments demonstrated that tNASP, but not sNASP is required for activation
of HSPA2.
Conclusions: Our results demonstrate that PC-3 and HeLa cancer cells require tNASP to maintain high levels of
HSPA2 activity and therefore viability, while PWR-1E cells are unaffected by tNASP depletion. These different cellular
responses most likely arise from changes in the interaction between tNASP and HSPA2 and disturbed tNASP
chaperoning of linker histones. This study has demonstrated that tNASP is critical for the survival of prostate cancer
cells and suggests that targeting tNASP expression can lead to a new approach for prostate cancer treatment.
Background
Nuclear Autoantigenic Sperm Protein (NASP) is a his-
tone chaperone that binds both core and linker histones
[1-4], with a higher affinity for linker histones than core
histones [5]; NASP is present in all dividing cells. First
characterized in rabbit testis [6] as a homologue to the
Xenopus oocyte histone binding protein N1/N2 [7,8],
NASP has been shown to transport linker histones into
the nucleus, transferring H1 histones onto DNA and
facilitating chromatin assembly [5]. NASP overexpres-
sion [9] as well as NASP depletion induced by siRNA
treatment [10] causes disruption in the cell cycle,
changes in gene expression profiles [10], and in mice
the NASP
-/- null mutation is embryonic lethal [11].
Transcribed from a single copy gene, NASP has two
splice variants: tNASP, which is found in cancer, trans-
formed, embryonic and germ cells and sNASP, which is
found in embryonic and somatic cells [2].
NASP appears to be a multifunctional chaperone
protein participating in a variety of regulatory path-
ways. In developing embryonic stem cells 356 network
connectivity episodes have been reported for NASP,
suggesting multiple direct protein-protein interactions
[12]. During meiosis in the mouse tNASP regulates
CDC2/cyclin B1 complex formation through the mod-
ulation of HSPA2 ATPase activity [13]; during nucleo-
some assembly in both DNA synthesis-dependent and
independent pathways CAF1 and HIRA are associated
with NASP [3,14]; and during DNA repair NASP is
associated with KU70 [15].
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ian cancer, which could be suitable for clinical testing in
high-risk populations [16]. Different types of cancer and
different stages of the same cancer have been demon-
strated to have specific expression profiles for NASP:
grade 1 and 2 of breast cancers show up regulation of
NASP compared to grade 3 [17]. Estrogen positive tumors
express more NASP then estrogen negative ones and simi-
larly sporadic versus BRCA1/BRCA2 mutation positive
tumors show different NASP signatures [18]. NASP has
become an important constituent of the “poor prognosis
signature” in breast cancer patients [19] and the “aggres-
sive tumor gene signature” in lung cancer patients [20].
Although NASP has been reported to be an important
prognostic marker in prostate cancer cells [21], it is not
clear if tNASP has a specific role is this cancer.
NASP expression is characteristic of all dividing cells,
but only cancer, germ, embryonic and transformed cells
have a high level of expression of the tNASP splice var-
iant. Consequently we asked the question: what charac-
terizes tNASP in rapidly dividing cells? The current study
was undertaken to specifically characterize depletion of
tNASP in three different cell lines (prostate cancer PC-3
cells; cervical cancer HeLa cells; non-tumorigenic trans-
formed prostate epithelial PWR-1E cells) and the cellular
pathways activated as a consequence.
This study has demonstrated that tNASP is critical for
the survival of prostate cancer PC-3 cells and suggests
that targeting tNASP expression can lead to a new
approach for prostate cancer treatment.
Methods
Materials
All chemicals and reagents used in this study were of
molecular biology grade. FuGENE
®6 Transfection
Reagent was purchased from Roche Applied Science
(Indianapolis, IN). QIAprep Miniprep, QIAquick PCR
purification kits, RNeasy mini kit, RNase-Free DNase
Set, and Effectene
® Transfection Reagent were pur-
chased from Qiagen (Valencia, CA). Restriction enzymes
and DNA ligase were obtained from NEB (New England
Biolabs, Ipswich, MA). Carboxyfluorescein diacetate,
succinimidyl ester (CFSE) and thymidine were pur-
chased from Sigma (Saint Louis, MO). RT
2 Profiler PCR
Array, RT
2 First Strand Kit, and RT
2 SYBR Green qPCR
Master Mix were purchased from SABiosciences Cor-
poration (Frederick, MD). Sequencing was performed at
the University of North Carolina at Chapel Hill auto-
mated sequencing facility. Mouse monoclonal anti p53
antibody (DO-1) and rabbit polyclonal anti-p21 antibody
(SC-397) were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). Rabbit cleaved caspase-3
(Asp175) antibody was a gift from Dr. Mohanish Desh-
mukh (Department of Cell and Developmental Biology,
University of North Carolina at Chapel Hill). Mouse
monoclonal antibody to HSPA2 (ab55290) was pur-
chased from Abcam Inc. (Cambridge, MA). Goat anti-
serum to full-length recombinant human tNASP
(AAH10105) was custom made by Bethyl Laboratories
(Montgomery, TX). Goat affinity purified specific anti-
tNASP antibody was prepared by absorbing the anti-
tNASP antiserum with recombinant sNASP until the
anti-tNASP antibody did not react with recombinant
sNASP on a Western blot.
Cell culture
PC-3, HeLa, and PWR-1E [22] cells were used in this
study. All the cells were obtained directly from the
American Type Culture Collection (ATCC, Manassas,
VA).
Northern blot analysis
Total RNA samples from cell cultures were purified
using RNeasy Mini Kit and blotted to Amersham
Hybond-N nylon membrane (GE Healthcare, Little
Chalfont, UK). The blots were probed with a
32P-labeled
750 base pair cDNA from the C-terminal of human
NASP, which is identical in sequence for both tNASP
and sNASP. Hybridization was carried out in QiuckHyb
solution (Agilent Technologies, Santa Clara, CA). Radio-
active bands were detected in a PhosphorImager Storm-
860 (Molecular Dynamics, Piscataway, NJ).
Indirect immunofluorescence
Cells were grown on chamber slides with polystyrene
wells (BD Biosciences, Bedford, MA), fixed with chilled
methanol (-20°C, 20 min) and incubated in goat affinity
purified specific anti-tNASP antiserum or pre-immune
serum (1:500 in 0.5% BSA in PBS), or in caspase-3 anti-
body (1:200) for 1 hour. After the washing in PBS twice,
cells were incubated in Alexa Flour
® 488 donkey anti-
goat IgG (1:4000 in 0.5% BSA in PBS, Molecular Probes,
Eugene, OR). Secondary antibody controls were included
in all experiments and were negative.
Senescence-associated b-galactosidase staining
PC-3, HeLa, and PWR-1E cells were plated on culture
slides (BD Biosciences, Bedford, MA) and treated by
tNASP shRNA or scrambled shRNA lentivirus. Four
days after treatment cells were stained for senescence-
activated b-galactosidase activity at pH 6 [23] using a
Senescence b-Galactosidase Staining Kit (Cell Signaling
Technology, Danvers, MA) accordingly the manufac-
turer’s instructions.
Double thymidine block
HeLa cells were blocked with thymidine to arrest all the
cells at the beginning of S phase [2]. The cells were
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and 8 hours after release and examined for DNA con-
tent by FACS.
Cell proliferation assay
The cell proliferation (cell division) assay was carried out
by labeling scrambled and tNASP shRNA treated PC-3,
HeLa, and PWR-1E cells with CFSE [24]. A stock solution
(5 mM CFSE in DMSO) was prepared and stored at -80°
C. Control and experimentally treated cells were trypsi-
nized, washed twice in sterile PBS and re-suspended in 2
ml of sterile PBS, pre-warmed to 37°C. The stock solution
of CFSE was used at a final concentration of 5 μMa f t e r
incubation at 37°C for 10 min in the dark. To quench the
labeling, cells were washed twice with DMEM cell culture
medium containing penicillin/streptomycin and 10% FBS.
Cells were allowed to grow for an additional 3 days. After
72 hours of growth, cells were washed by PBS, trypsinized,
washed in PBS, fixed in 70% ethanol for 2 hours, and
stained with tNASP specific antiserum. A parental popula-
tion of cells was obtained by labeling cells followed by
their immediate fixation in 70% ethanol.
Fluorescent-activated cell sorting (FACS) analysis
Scrambled and tNASP shRNA treated cells 0, 4, and 8
hours after release from the double thymidine block
were washed with PBS, trypsinized, and fixed with 70%
ethanol for ≥ 2 h on ice. Cells were immunostained
with goat anti-tNASP affinity purified antibody, washed
twice in PBS and stained with secondary antibody Alexa
Fluor 647 donkey anti-goat IgG (H+L) A21447 (Invitro-
gen, Eugene, OR). Cells were washed in PBS and stained
for 30 min at 37°C with 50 μg/ml propidium iodide in
PBS (containing 200 μg/ml RNAse A and 0.1% Triton
X-100), and incubated overnight at 4°C before analysis
a tt h eU n i v e r s i t yo fN o r t hC a rolina at Chapel Hill Flow
Cytometry Facility on a Dako Cyan ADP flow cytometer.
For each sample at least 10,000 cells were counted.
After gating out doublets and debris, cell cycle distribu-
tion was analyzed using Summit version 4.3 software
(Dako Colorado, Inc., Fort Collins, CO). For the cell
proliferation assay, CFSE labeled cells were fixed in 70%
ethanol for at least 2 hours and immunostained with
specific anti-tNASP antibodies as described above.
Construction of lentivirus to express shRNA targeting
human tNASP
Designing shRNA oligos for pLKO.1
For selection of 21-mer targets within the human t-
NASP specific part of the sequence (NM_002482), we
used an automated service provided by the Broad Insti-
tute [25]. Out of more than 200 possible targets 10 top-
scoring targets were selected for further study. Forward
and reverse oligos compatible with pLKO.1 [26] were
designed and produced in the UNC Oligonucleotide
Synthesis Core Facility. Annealing of forward and
reverse oligonucleotides was carried out in a PCR
machine at 95°C for 4 min, 70°C for 10 min with slow
cooling to room temperature over 4 hours. The vector
pLKO.1 was sequentially digested by Age1 and EcoR1
restriction enzymes and ligated with annealed oligonu-
cleotides using NEB T4 DNA ligase. The ligated con-
struct was propagated in DH5a cells. Plasmids were
purified with a Miniprep kit and successful ligations
were verified by a sequencing reaction. Individual
tNASP shRNA constructs were screened using Effec-
tene
® Transfection Reagent for transient knockdown of
tNASP mRNA levels in easy to transfect HeLa cells. The
two most active shRNA constructs were selected and
used for the production of lentiviral particles.
Lentiviral particles
Both packaging plasmid psPAX2 and envelope plasmid
pMD2.G were obtained from Addgene [27]. Lentiviral
particles were generated in HEK-293T cells. Plasmids
were transfected using FuGENE
®6 Transfection Reagent.
Target cells were infected by adding lentiviral particles
to growth medium. For better transfection polybrene
(hexadimethrine bromide, final concentration 8 μg/ml)
was added to the culture medium. Infected cells were
selected by puromycin pressure added to a final concen-
tration of 3 μg/ml. Negative controls were the mock
transfection with Addgene plasmid 1864. The sequence
of this shRNA does not have any cellular target [28].
RT
2Profiler PCR Array
RT
2 Profiler PCR Array was used as a method of com-
bining real-time PCR performance with a simultaneous
analysis of a panel of genes related to the cell cycle
(array PAHS-020D. Preparation and analysis of samples
were carried out in accordance with the manufacturer’s
recommendations. Arrays were run on an Opticon 2
thermal cycler (Bio-Rad, Hercules, CA). Threshold cycle
values were analyzed using web-based PCR array data
analysis software [29]. Reverse transcriptase control,
cDNA control, and positive PCR control were within
the accepted range.
Colorimetric determination of ATPase activity (Malachite
Green Assay)
The amount of inorganic phosphate liberated by HSPA2
in the presence of tNASP or sNASP was determined by a
malachite green assay [30] based on the formation of a
phosphomolybdate complex as we previously described
for HIST1H1T [13]. Protein concentrations were 0.5 μM
for HSPA2, CDC2, tNASP, sNASP and HIST1H1A. Sig-
nificance was determined by the Student t-test.
Results
In order to investigate the functions of tNASP we com-
pared three cell lines: the prostate cancer cell line PC-3,
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tumorigenic prostate epithelial cell line PWR-1E. Initi-
ally we found that HeLa cells transiently transfected
with tNASP specific shRNA using Effectene lost tNASP
mRNA within 4 days after transfection without affecting
the mRNA levels of splice variant sNASP (Figure 1).
PC-3, HeLa, and PWR-1E cells were treated with lenti-
viral particles expressing either tNASP shRNA or
scrambled shRNA as a negative control and changes in
the amount of tNASP protein were examined by Wes-
tern blotting. While HeLa and PWR-1E cells showed a
reduction in tNASP protein after 6 days of treatment,
the level of tNASP protein in PC-3 cells by that time
was almost undetectable (Figure 2). To determine if the
r e d u c t i o ni nt N A S Pp r o t e i nw a st h er e s u l to fag e n e r a l
decrease of tNASP in all cells or a selective depletion in
a group of cells, all three cell types were treated with
either lentiviral particlese x p r e s s i n gt N A S Ps h R N Ao r
scrambled shRNA and immunostained with anti-tNASP
antibody 9 days after treatment. HeLa cells were
depleted of tNASP in their nuclei (Figure 3C,D)
compared to the control (scrambled) treated cells that
showed strong nuclear staining for tNASP (Figure 3A,
B). A few cells (< 5%) had a strong tNASP signal in the
cytoplasm and nucleus. PC-3 cells showed complete
depletion of tNASP (Figure 3G,H) in their nuclei
whereas control treated PC-3 cells showed strong
nuclear staining (Figure 3E,F). PWR-1E cells showed a
significant reduction in tNASP, although not to the
same extent as HeLa and PC-3 cells. A few PWR-1E
cells had tNASP in the cytoplasm and nucleus (Figure
3I,J,K, and 3L). Based on the results of immunostaining,
tNASP shRNA treatment efficiently depleted tNASP
protein from PC-3, HeLa and PWR-1E cells. However,
the level and pattern of depletion was different in the
three cell types; most complete depletion was observed
in PC-3 cells, while HeLa and PWR-1E showed less
effective depletion. The morphology of the tNASP-
depleted and tNASP-containing cells based solely on
phase contrast microscopy was indistinguishable, except
for an increase in dark granules in the cytoplasm of
tNASP deficient cells.
Changes in cell number
To determine if the depletion of tNASP affects cell pro-
liferation and survival, we first studied the changes in
cell numbers. As shown in Figure 4, the three cell lines
were treated with either lentiviral particles expressing
tNASP shRNA or scrambled shRNA on day 1. During
the first 2-3 days neither treatment group showed any
increase in the cell numbers, which was probably a
reflection of the general cytotoxicity of lentiviral and
puromycin selection treatments. Starting on day 5 for
HeLa cells (Figure 4A) and day 3 for PC-3 cells (Figure
4B) a difference between experimental and control trea-
ted cells became apparent in that the number of control
treated cells began to increase, while the number of
experimentally treated cells remained relatively
unchanged. In striking contrast, the number of PWR-1E
cells in the experimental and control groups did not dif-
fer significantly from each other, although generally the
number of cells in the control group was higher. The
fluctuations in PWR-1E cell numbers were probably due
to their increased sensitivity to growth conditions [31].
As a result of these experiments we asked whether the
decline in the number of cells was due to cell death or
was the result of a decreased proliferation rate.
Affect of tNASP depletion on cell proliferation
As described above (Figure 3), there was some variation
among individual cells within a cell line with regard to
the amount of tNASP decrease as a result of tNASP
shRNA lentiviral treatment. Using anti-tNASP antibo-
dies we determined by FACS the distribution of tNASP-
positive and tNASP-negative cells on day 6 (upper
Figure 1 Northern blot analysis of total RNA from HeLa cells.
Line 1: HeLa cells treated with tNASP shRNA; line 2: HeLa cells
treated with scrambled shRNA; line 3: untreated HeLa cells. Blot was
hybridized with the 750 bp sequence common to both tNASP and
sNASP. Lower panel shows GAPDH loading control. Figure 1 is a
representative result from a total of 3 experiments.
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cells depleted of tNASP (red line histogram) and tNASP
containing cells (blue line histogram). The highest num-
ber of tNASP depleted cells was observed in the PC-3
cell sample, corresponding to the observations from
immunostaining (Figure 3).
Only the tNASP depleted cells were gated in the fol-
lowing FACS experiments and used for the proliferation
assay. To determine the position of undivided cells
(called the parental population) a portion of the PC-3,
HeLa, and PWR-1E cells was labeled with CFSE, a pro-
tein stain, after tNASP shRNA treatment and immedi-
ately fixed. The CFSE labeling in each group of cells is
shown as the parental population in Figure 5B,F, and 5J
and marks the position of the original amount of CFSE
in each cell line. The experimental and control trans-
fected cells were labeled with CFSE on day 3 after treat-
ment and grown for an additional 3 days. Control HeLa
cells (Figure 5C) show three distinct peaks (from arrow,
right to left in Figure 5C) representing three cell division
cycles with no cells remaining undivided (the amount of
CFSE in all 3 peaks is equal to that in the original par-
ent population) and 81% of the cells completed the
third division. In contrast 48% of tNASP shRNA treated
HeLa cells could not complete the first division (Figure
5D), 34% completed the first division and only 18%
could complete the second and third divisions.
Control treated PC-3 cells examined under identical
experimental conditions to the HeLa cells completed
either one or two divisions by day 3 (Figure 5G): 71%
completed two divisions, 28% completed one division,
and 1% did not divide. In contrast, proliferation was sig-
nificantly affected in tNASP shRNA treated cells: 46%
completed two divisions, 51% completed only one divi-
sion, and 3% of cells did not divide (Figure 5H). PWR-1E
cells were distinct from both HeLa and PC-3, under iden-
tical conditions they completed 2 divisions and there was
no difference between experimental and control
(scrambled) treated cells (Figure 5K,L). These experi-
ments demonstrate that depletion of tNASP has distinct
effects on different cell lines, retarding cell cycle prolif-
eration in PC-3 and HeLa cells but not in PWR-1E cells.
Cell cycle progression
We next determined the phase of the cell cycle in which
the proliferation of tNASP depleted cells was blocked.
Figure 2 Western blot analysis of cell lysates after tNASP shRNA treatment demonstrating changes in protein expression in HeLa, PC-
3, and PWR-1E cells 6 days after treatment. Line 1 of each panel: untreated control; line 2 of each panel: scrambled shRNA treatment; line 3
of each panel: tNASP shRNA treatment. Beta actin was used as a loading control. Figure 2 is a representative result from a total of 3 experiments.
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control (scrambled, dotted line) treated HeLa cells were
synchronized by a double thymidine block and observed
for their progression through the cell cycle. As in the
proliferation assay (Figure 5) only tNASP depleted cells
were gated in the FACS experiments. At the time of
release (Figure 6, 0 hours panel) from the double thymi-
dine block both groups of cells looked identical; 78.5%
of tNASP shRNA treated cells and 83.3% of scrambled
shRNA treated cells were in G1 phase. After 8 hours
more than 80% of control treated cells replicated their
DNA and moved to the G2 phase, however less than
50% of tNASP shRNA treated cells moved to the G2
phase. 42.9% of tNASP shRNA treated cells remained in
G1 phase, compared to 13% of the control treated cells
(Figure 6; 8 hours panel). These data indicate that cells
depleted of tNASP are held in the G1 phase.
Senescence or apoptosis
We next asked the question: what happens to the
tNASP depleted PC-3 and HeLa cells? To determine if
the cells undergo senescence we tested for b-galactosi-
dase activity at pH 6, which is a known characteristic of
senescent cells [32]. PC-3, HeLa, and PWR-1E tNASP
Figure 3 Localization of tNASP in HeLa, PC-3 and PWR-1E cells. For each cell type the upper panel shows phase contrast images with the
same field below immunostained with anti-tNASP antibody after scrambled shRNA treatment: (A, B) HeLa cells; (E, F) PC-3 cells; (I, J) PWR-1E
cells. The lower panel shows phase contrast images with the same field below immunostained with anti tNASP antibody after tNASP shRNA
treatment: (C-D) HeLa cells; (G-H) PC-3 cells; (K-L) PWR-1E cells. Scale bar = 20 μm for all panels.
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(data not shown). To determine if the cells undergo
apoptosis we stained the tNASP depleted cells for active
caspase-3, which is a marker for early apoptosis and
indicative of cells in the apoptosis pathway [33,34]. Four
days after tNASP shRNA treatment PC-3, HeLa and
PWR-1E cells were immunostained with antibody to
cleaved caspase-3. As shown in Figure 6B staining
reveled that numerous tNASP depleted PC-3 and HeLa
cells contained activated caspase-3 (Figure 6B; a-b; c-d).
Control treated cells were negative for activated cas-
pase-3 (data not shown). In contrast to PC-3 and HeLa
cells, tNASP depleted PWR-1E cells were negative for
caspase-3 (Figure 6B; e-f). These data indicate that in
PC-3 and HeLa cells the depletion of tNASP induces
apoptosis, in contrast to non-tumorigenic PWR-1E cells
in which proliferation is unaffected and apoptosis is not
induced.
Gene expression profiles
Because NASP is a multifunctional chaperone protein
that may interact with a variety of other proteins we
analyzed the gene expression profiles by real time PCR
using RT
2 PCR arrays in PC-3, HeLa, and PWR-1E cells
depleted of tNASP. Experimental and control treated
cells were sampled four days after treatment when the
difference in cell number first becomes apparent. Genes
that were up or down regulated by at least two fold are
shown in Table 1. Cyclin-dependant kinase inhibitor 1A
(p21) was the only up regulated gene common to all
three cell types. Additionally HeLa and PWR-1E cells
showed a common up regulation of cyclin-dependant
kinase 6. There were no common down regulated genes,
although cyclin D1 and cyclin D2 were down regulated
in PC-3 and PWR-1E cells respectively.
Expression of p21
Expression of p21 was confirmed by Western blots six
days after treatment. As shown in Figure 2, p21 is up
regulated in PC-3 and HeLa cells but not in PWR-1E
cells. The protein p21 is a well established inhibitor of
cyclin-CDK2 or cyclin-CDK4 complexes and functions
as a regulator of cell cycle progression at G1, consistent
with our findings in the cell cycle analysis.
HSPA2 activity
To elucidate the mechanism of anti-proliferative and
pro-apoptotic effects of tNASP depletion in prostate
cancer cells we examined HSPA2 ATPase activity.
HSPA2 is required for the survival of cancer cells;
HSPA2 depletion has been reported to arrest cells in G1
and up regulate p21 expression [35]. However, non-
Figure 4 Dynamic changes in cell number for HeLa, PC-3, and
PWR-1E cells treated with tNASP shRNA and scrambled shRNA.
The Y axis indicates the number of cells. The X axis indicates days.
The treatment with tNASP shRNA or scrambled shRNA occurred on
day 1. The error bars represent ± S.D. The asterisks indicate
significantly different values (p < 0.05).
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Page 7 of 13Figure 5 Depletion of tNASP from HeLa and PC-3 cells decreases cell proliferation. Upper panel “tNASP content” ( A ,E ,I )s h o w st h e
distribution of tNASP depleted and tNASP containing cells after the tNASP shRNA treatment as determined by FASC analysis on day 6. Panel
“Parental population” (B, F, J) shows the original position of labeled, non-dividing cells on day 3. Panels “Scrambled shRNA” (C, G, K) and “tNASP
shRNA” (D, H, L) show the proliferation of cells after they were treated by tNASP shRNA or scrambled shRNA. Each peak shows the population of
cells with diminished content of CFSE due to cell divisions. Data were collected on day 6. Only tNASP depleted cells were analyzed for
proliferation, tNASP containing cells were gated out. Figure 5 is a representative result from a total of 3 experiments.
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Page 8 of 13Figure 6 tNASP depleted cells slow their progression through the cell cycle and develop apoptosis markers. A.F A C Sa n a l y s i s
demonstrating double thymidine-blocked HeLa cells allowed to progress in synchrony through the cell cycle. Solid line: HeLa cell progression
through the cell cycle after treatment with tNASP shRNA; Dotted line: HeLa cell progression after treatment with scrambled shRNA. B.
Immunostaining for caspase-3 in HeLa, PC-3, and PWR-1E cells after treatment with tNASP shRNA. Scale bar = 20 μm for all panels. Upper panel
shows phase contrast images and lower panel shows corresponding immunostaining for caspase-3. HeLa cells (a, b); PC-3 cells (c, d); PWR-1E
cells (e, f). Control caspase-3 staining of scrambled shRNA treated cells was negative for all samples (data not shown).
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tion of HSPA2 [36]. Previously we reported that in
mouse spermatogenic cells HSPA2 ATPase activity
increased after interaction with tNASP in the presence
of linker histone H1t, cyclin B1 and CDC2 [13]. Using
an identical experimental paradigm we compared the in
vitro modulation of HSPA2 ATPase activity by tNASP
or sNASP in the presence of cyclin B1, CDC2 and his-
tone H1a. Histone H1a was selected because it is the
linker histone with the highest level of expression in
somatic cells [37]. As shown in Figure 7 we found that
HSPA2 was three times more active in the presence of
tNASP than in the presence of sNASP. These results are
consistent with PC-3 and HeLa cells requiring tNASP to
maintain high levels of HSPA2 activity to remain viable
while PWR-1E cells remain viable and are insensitive to
lower levels of HSPA2 activity.
Discussion
This study has demonstrated that selective depletion of
tNASP from PC-3, HeLa and PWR-1E cell lines in cul-
ture leaves sNASP unaffected and results in distinctly
different effects. Using lentiviral expression of tNASP
shRNA, all three cell lines had decreased HSPA2 protein
levels, yet only PC-3 and HeLa cells increased expres-
sion of p21 and entered apoptosis. NASP has been
detected in all dividing cells, but only cancer, trans-
formed, germ, and embryonic cells have a high level of
expression of the tNASP splice variant [2]. Depletion of
both tNASP and sNASP has been shown to be
Table 1 Cell cycle related genes regulated by the depletion of tNASP
Gene name
1 Gene Symbol (GenBank)
2 Fold change
HeLa cells
Cyclin-dependent kinase inhibitor 1A (p21) CDKN1A (NM_000389) 3.67
Cyclin-dependent kinase 6 CDK6 (NM_001259) 2.69
PC-3 cells
Cyclin D2 CCND2 (NM_001759) 12.45
Cyclin-dependent kinase inhibitor 2A (p16) CDKN1A (NM_000389) 2.87
Beta-2-microglobulin B2M (NM_004048) 2.52
Cyclin G2 CCNG2 (NM_004354) 2.46
Cyclin-dependent kinase inhibitor 1A (p21) CDKN2A (NM_000077) 2.45
Cyclin B2 CCNB2 (NM_004701) 2.4
HUS1checkpoint homolog HUS1(NM_004507) -2.15
Cullin2 CUL2 (NM_003591) -2.6
Cyclin D1 CCND1 (NM_053056) -9.69
PWR-1E
CDC28protein kinase regulatory subunit 2 CKS2 (NM_001827) 4.38
Cyclin-dependent kinase inhibitor 1A (p21) CDKN1A(NM_000389) 2.45
Cyclin G2 CCNG2 (NM_004354) 2.42
Cyclin-dependent kinase inhibitor 1B (p27) CDKN1B (NM_004064) 2.40
Cyclin-dependent kinase 6 CDK6 (NM_001259) 2.25
Cyclin F CCNF (NM_001761) 2.24
Cyclin D2 CCND2 (NM_001759) -2.38
B-cell Cell/lymphoma 2 BCL2 (NM_000633) -2.83
1 Genes listed present those differentially regulated after HeLa, PC3, RWPE-2, and PWR-1E cells were infected by lentiviral particles containing tNASP shRNA as
compared to cells infected with scramble shRNA. The cutoff limit in the analysis was set to two-fold for both induced (+) and repressed (-) genes.
2 Gene Bank accession number
Figure 7 tNASP, not sNASP activates the ATPase activity of
HSPA2. ATPase activity of HSPA2 is presented as inorganic
phosphate (μM) liberated by HSPA2 within 60 min of incubation at
37°C in the presence of tNASP or sNASP, CDC2, and histone H1a.
Data are represented as mean ± SD. The asterisks indicate
significantly different values (p < 0.05). Figure 7 is a representative
result from a total of 3 experiments.
Alekseev et al. Reproductive Biology and Endocrinology 2011, 9:50
http://www.rbej.com/content/9/1/50
Page 10 of 13embryonic lethal and without sufficient NASP HeLa and
U2OS cells were unable to enter S phase [11]. However,
these studies did not distinguish whether tNASP and
sNASP played separate roles and raised the question
why rapidly dividing cells such as cancer or embryonic
cells expressed tNASP while adult somatic cells did not.
The results reported in this study clearly demon-
strated that in prostate cancer PC-3 cells and cervical
cancer HeLa cells depletion of tNASP caused significant
anti-proliferative effects and induced apoptosis while the
non-tumorigenic prostate epithelial PWR-1E cells did
not experience these changes in the time span observed.
Cells depleted of tNASP slowed down their proliferation
and were blocked at the G1/S border of the cell cycle,
which is consistent with our earlier report [11].
The activation of p53 could result in apoptosis, cell-
cycle arrest, DNA repair or senescence [38,39]; however
activation of p53 is not relevant in our study because we
used cell lines with non-functional, inhibited or mutated
p53. HeLa cells, which originate from adenocarcinoma
of the cervix, contain wild-type p53 alleles together with
the DNA of specific types of human papillomaviruses
[40] and the transcriptional stimulatory activity of HeLa
cell p53 is strongly repressed by one of the oncogenic
papilomavirus products, E6 protein [41]. In PC-3 pros-
tate cancer cells p53 is absent due to deletion of a base
pair in the single copy gene and that generates a frame
shift and a new immediate stop codon [42,43]. PWR-1E
cells were immortalized by adenovirus 12-SV40 and
although they show strong nuclear staining for p53 [22]
its activity is inhibited by the binding between p53 and
SV40 Large T-antigen [44]. In this study p53 protein
could only be detected on Western blots in PWR-1E
cells (Figure 2).
The up regulation of p21 appears to be important in
the cell lines we studied. Expression of p21 mRNA
increased in all three cell lines; however protein levels
were increased only in PC-3 and HeLa cells. p21 is
known to be a potent cell cycle progression inhibitor
because it inhibits the activity of cyclin-dependant
kinase-cyclins A, D, and E complexes [45]. Although it
is well established that p21 mediates p53-dependant G1/
S phase growth arrest in response to DNA damage
[46,47], p21 expression could be induced by mechan-
isms independent of p53. In this case the expression of
p21 is up regulated by different transcription factors:
E2F1 through the activation of Ras [48], SP1, SP3, AP2,
HOXA10, STAT [49], AP-1 [50].
Because tNASP is a chaperone for linker histones
and transports them into the nucleus in an energy and
nuclear localization signal-dependent manner [51], the
depletion of tNASP implies that there could be a
simultaneous depletion of H1 histones in the nucleus.
Depletion of linker histones has been reported to be
sufficient for altering the expression of subsets of
genes, the up regulation of p21 in particular, and for
G1-phase cell cycle arrest in human breast cancer cells
[52]. Regulation of DNA replication through multiple
pathways in egg extracts has been reported to be
dependent on sufficient linker histones [53]. Decreased
levels of H1 histones down to 50% from their normal
level caused profound chromatin structural changes,
including global nucleosome spacing, reduced chroma-
tin compaction, and decreases in core histone modifi-
cations [54]. Moreover, linker histones are critical for
the interaction of tNASP and HSPA2. We previously
reported [13] that in mouse spermatogenic cells
tNASP in the presence of CDC2 requires H1 linker
histones to significantly increase HSPA2 ATPase activ-
ity. Therefore, depletion of tNASP should result in les-
ser amounts of HSPA2 activity implying that the
interaction of tNASP and HSPA2 may be an important
factor in the differential response of cancer cell lines
to the depletion of tNASP. All three cell types in
this study showed a decrease in HSPA2 protein levels
(Figure 2) and the ATPase activity of HSPA2 was sig-
nificantly increased in the presence of tNASP, but not
sNASP (Figure 7).
HSPA2 activity was previously reported as a necessary
chaperone for formation of an active CDC2-cyclin B1
complex in pachytene spermatocytes as a condition for
successful completion of the G2/M transition [55].
HSPA2 is not only essential for spermatogenesis [56],
but is required for tumor cell growth and survival [57].
HSPA2 depletion resulted in a senescence-like condi-
tion, arrest in the G1 phase of the cell cycle and up or
down regulation of genes such as MIC-1 and p21 [35].
Interestingly HSPA2 is required for survival of cancer
cells [35], while non-tumorigenic cells (mammary MCF-
10A, HBL-100, and prostate PNT1A) displayed no
changes in survival after depletion of HSPA2. This selec-
tive effect is similar to our observation that although
PWR-1E cells lost HSPA2 protein their survival was not
affected.
Conclusions
Based on our data we conclude that the effect of tNASP
depletion could be signaled through at least two differ-
ent pathways: a loss of HSPA2 activity and a shortage of
linker or core histones. Either of these pathways might
lead to inhibited proliferation and apoptosis. The data
presented here demonstrate that tNASP is required for
the survival of prostate cancer PC-3 cells and its deple-
tion results in anti-proliferative and pro-apoptotic activ-
ity. Targeting tNASP expression could lead to a new
approach for cancer treatment.
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